Stay updated on Enfortumab Vedotin Combinations in Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Enfortumab Vedotin Combinations in Urothelial Cancer Clinical Trial page.

Latest updates to the Enfortumab Vedotin Combinations in Urothelial Cancer Clinical Trial page
- Check2 days agoChange DetectedThe study EV-103 (NCT03288545) was terminated by the sponsor after meeting enrollment targets and primary objectives, with data collected for planned regulatory filings. The page updates recruitment status to reflect termination, including removal of the 'Active, not recruiting' designation and related dates.SummaryDifference0.2%

- Check9 days agoChange DetectedAdded revision: v3.5.0. Removed revision: v3.4.3.SummaryDifference0.0%

- Check16 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check23 days agoNo Change Detected
- Check45 days agoChange DetectedPage now shows Revision: v3.4.2. The funding-lapse notice and the prior Revision: v3.4.1 text were removed.SummaryDifference0.2%

- Check52 days agoChange DetectedAdded a government funding/operational status banner notifying potential delays and that the NIH Clinical Center is open; also updated the page revision from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check59 days agoChange DetectedAdded a Show glossary toggle and new Last Update metadata fields (Last Update Submitted that Met QC Criteria, Last Update Posted) and updated the No FEAR Act Data notice. Revision updated to version 3.4.0.SummaryDifference0.1%

Stay in the know with updates to Enfortumab Vedotin Combinations in Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Enfortumab Vedotin Combinations in Urothelial Cancer Clinical Trial page.